Compare Intuit Inc. (INTU) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuit Inc. vs Eli Lilly And Co — how do they compare? Intuit Inc. trades at $303.5 (market cap $81.21B), while Eli Lilly And Co trades at $1,167.63 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 12.8× Intuit Inc.'s market cap, and Intuit Inc. pays the higher dividend (1.82%). Which is the better fit depends on your goals — on Pluang, investors hold Intuit Inc. for 66 Days and Eli Lilly And Co for 93 Days on average.
| INTU | LLY | |
|---|---|---|
Market Cap | $81.21B | $1.04T |
Volume | 5,165,806 | 3,064,878 |
Sector | Technology | Health |
52-Week High | $683.39 | $1.28K |
52-Week Low | $255.07 | $799.57 |
Typical Hold Time | 66 Days | 93 Days |
Enterprise Value | $82.43B | $1.09T |
Dividend Yield | 1.82% | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuit (INTU) trades at $303.88, up 4.85% today, with strong fundamental performance including 21.3% net income margin and consistent earnings beats. The stock shows bullish technical momentum with resistance at $308 and support at $293. Recent financials reveal robust revenue growth from $18.8B in 2025 to projected $21.4B in 2026, though legal challenges from class action lawsuits present near-term headwinds.
Outlook remains positive with analyst consensus target of $379.68 (25% upside), driven by AI integration and QuickBooks monetization. Key risks include litigation overhang and competitive pressures in financial software. Institutional sentiment leans bullish with 60% buy ratings, supporting long-term growth trajectory despite technical overbought signals.
Eli Lilly (LLY) trades at $1,188.72, up 2.7% on the day, with a bullish technical signal and strong fundamentals. Recent earnings beats, robust revenue growth to $65.18B in 2025, and a net income margin of 33.53% highlight operational strength. Positive news flow centers on next-generation weight-loss drugs, with analyst consensus bullish and a price target of $1,350.
Outlook remains positive given pipeline catalysts in obesity/diabetes markets, though high valuations (P/E 39.9) and rising debt levels pose risks. Competitive intensity and regulatory scrutiny are watchpoints, but institutional support and earnings momentum underpin further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
